Region
CDMOs in Europe
Compare European CDMOs with EMA-compliant facilities across Germany, Switzerland, Ireland, and the broader EU. Filter by specialization, scale, and regulatory approvals.
926 companies listed
European CDMO Manufacturing
Europe is the second-largest pharma manufacturing region globally, with particular strengths in biologics, API synthesis, and sterile manufacturing. Germany leads in both volume and technological capability, followed by Switzerland (home to major CDMO headquarters), Ireland (a biologics manufacturing hub driven by favorable tax policy), and Italy (strong in API and generics).
EMA regulation provides mutual recognition advantages. A GMP certificate from one EU member state is recognized across the bloc, simplifying multi-market filings. The EMA also maintains Mutual Recognition Agreements (MRAs) with regulators in the US, Canada, Australia, Japan, and other markets, meaning European GMP inspections are often accepted by foreign authorities.
How does pricing compare? European CDMOs typically cost 10-30% more than Asian alternatives but offer shorter lead times for European and US sponsors, stronger IP protection, and established regulatory relationships. For high-value biologics and specialty products, the total cost of quality often favors European manufacturing.
Browse Europe CDMOs by country
Every country below has its own page with a ranked CDMO list, a country-zoomed facilities map, and the local regulatory picture. Counts are live manufacturing-site totals.
Companies (926)
HAS Healthcare Advanced Synthesis SA
Switzerland
HAS Healthcare Advanced Synthesis SA, based in Biasca, Switzerland, is a full-service CDMO with over 40 years of experience in pharmaceutical development and manufacturing. The company recently acquired Cerbios-Pharma SA to create a leading international CDMO group, backed by 65 Equity Partners.
Small Molecule APIFormulation DevelopmentAnalytical Services
HealthTech BioActives (HTBA)
Spain
HealthTech BioActives (HTBA) is a Spanish company and global leader in citrus flavonoids and Vitamin B12 active forms, with over 45 years of experience. The company specializes in the clean production of naturally sourced active pharmaceutical ingredients and nutraceutical ingredients from its manufacturing facilities in Murcia, Spain.
Frequently Asked Questions
What are the advantages of European CDMOs?+
Strong regulatory framework with EMA GMP compliance recognized globally. Mutual Recognition Agreements reduce the need for duplicate inspections. Deep talent pool in biotechnology and chemistry. Proximity to European markets and established distribution networks. Strong intellectual property protection under EU law. Many European CDMOs also hold FDA registration for US-market products.
How does EMA regulation compare to FDA?+
Both agencies enforce cGMP standards, but the processes differ. EMA uses a centralized procedure for EU-wide marketing authorization with national agencies conducting GMP inspections. FDA directly inspects manufacturing facilities. The EMA-FDA MRA means each agency can rely on the other's inspection findings, reducing duplication. Key difference: EMA requires a Qualified Person (QP) for batch release -- a role that does not exist in the US system.
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
